Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accrued Expenses (Details)

v3.22.2
Schedule of Accrued Expenses (Details) - USD ($)
Jun. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Payroll and incentives $ 974,000 $ 1,343,000
General and administrative expenses 404,000 195,000
Research and development expenses 376,000 381,000
Deferred revenue * [1] 2,096,000 33,000
Other deferred liabilities ** [2] 444,000 899,000
Total $ 4,294,396 $ 2,850,888
[1] At June 30, 2022, the balance included $2,063 thousand related to the BioNTech Agreement and $33 thousand is related to the Genentech Agreement. At December 31, 2021, the balance of $33 thousand of deferred revenue was related to the Genentech Agreement. The balance of the BioNTech Agreement will be recognized evenly over the next nine months. (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).
[2] At June 30, 2022, the balance of $444 thousand is related to the CFF Agreement’s deferred liability. At December 31, 2021, the balance of $899 thousand was related to the CFF Agreement’s deferred liability. (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).